EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

S‐ and R‐Carvedilol Prevent Benzo(a)pyrene‐Induced Lung Carcinogenesis

Ayaz Shahid iD, Steven Yeung, Bradley T Andresen, Ying Huang

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Ayaz Shahid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA. Hauptthemen laut MEDLINE: Benzo(a)pyrene, Carvedilol, Lung Neoplasms, Carcinogenesis. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the most common and deadly type of cancer. Our previous study showed that carvedilol, a β‐blocker, can prevent lung cancer induced by benzo(a)pyrene [B(a)P]. Carvedilol is a 1:1 racemic mixture of S‐ and R‐carvedilol, with S‐carvedilol acting as a β‐adrenergic blocker, while R‐carvedilol lacks β‐blocking activity. Despite this, a previous study showed that R‐carvedilol effectively prevents UV‐induced skin cancer. This study aimed to determine whether carvedilol's lung cancer prevention relies on its β‐blocking activity. We compared the effectiveness of S‐ and R‐carvedilol in preventing lung cancer induced by B(a)P and its metabolite, benzo(a)pyrene diol epoxide (BPDE), both in vivo and in vitro. Our results showed that S‐ and R‐carvedilol equally prevent malignant transformation of the human bronchial epithelial cell line (BEAS‐2B) induced by BPDE. Furthermore, both S‐ and R‐carvedilol significantly inhibit the B(a)P‐induced activation of the aryl hydrocarbon receptor (AhR)/xenobiotic responsive element (XRE) and mRNA expression of CYP1A1 in BEAS‐2B cells. In mice, daily administering S‐ or R‐carvedilol for 7 days before exposing them to B(a)P resulted in a significant decrease in the levels of lactate dehydrogenase and malondialdehyde and prevented inflammatory cell infiltration and histopathologic abnormalities in mouse lungs. Exposure to B(a)P caused the development of lung tumors, but treating the mice with S‐ or R‐carvedilol for 23 weeks significantly reduced the number and size of these tumors. The results were confirmed by H&E‐stained images of the mouse lungs. These findings support the hypothesis that carvedilol prevents B(a)P‐induced lung inflammation and carcinogenesis independently of β‐blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzo(a)pyreneCarvedilolLung NeoplasmsCarcinogenesisAnimalsHumansMiceCytochrome P-450 CYP1A1

Stichwörter der Autor:innen

R‐carvedilolbenzo(a)pyrenechemopreventionlung cancertobacco smokingβ‐Blockaders

Substanzen

Benzo(a)pyreneCarvedilolCytochrome P-450 CYP1A1

Autor:innen und Institutionen

  • Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA.

ORCID-Profile: Ayaz Shahid

Förderung

  • National Cancer Institute of the National Institutes of Health

Zitieren

APA

Shahid, A., Yeung, S., Andresen, B. T., & Huang, Y. (2025). S‐ and R‐Carvedilol Prevent Benzo(a)pyrene‐Induced Lung Carcinogenesis. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70109

Vancouver

Shahid A, Yeung S, Andresen BT, Huang Y. S‐ and R‐Carvedilol Prevent Benzo(a)pyrene‐Induced Lung Carcinogenesis. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70109

BibTeX
@article{Shahid2025,
  author = {Shahid, Ayaz and Yeung, Steven and Andresen, Bradley T and Huang, Ying},
  title = {S‐ and R‐Carvedilol Prevent Benzo(a)pyrene‐Induced Lung Carcinogenesis},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70109}
}
Kostenlos starten →